Drugs / CM082
Trials 36 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 112 trials | ||||||
| Phase 1 | NCT04434326 | Jul → Oct 2021 | neoplasm | AnewPharma | Completed | No outcome recorded |
| Phase 1 | NCT04747197 | Jan 2021 → May 2022 | wet macular degeneration | EyePoint Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04126668 | Dec 2019 → Jan 2020 | cancer | AnewPharma | Completed | No outcome recorded |
| Phase 1 | NCT04222842 | Dec 2019 → Dec 2021 | choroidal neovascularization | AnewPharma | Suspended | No outcome recorded |
| Phase 1 | NCT03792958 | Feb 2019 → Jun 2023 | cancer | AnewPharma | Unknown | No outcome recorded |
| Phase 1 | NCT03511222 | Sep 2018 → Aug 2019 | gastric cancer, gastroesophageal junction adenocarcinoma, hepatocellular carcinoma | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 1 | NCT03286244 | Mar 2018 → Aug 2019 | gastric cancer | AnewPharma | Unknown | No outcome recorded |
| Phase 1 | NCT02577458 | Sep 2015 → Mar 2018 | renal cell carcinoma | AnewPharma | Unknown | No outcome recorded |
| Phase 1 | NCT02452385 | Mar 2015 → Jun 2020 | age-related macular degeneration | AnewPharma | Suspended | No outcome recorded |
| Phase 1 | NCT02146222 | Sep 2014 → Dec 2016 | cancer of unknown primary site | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 1 | NCT01863485 | May 2013 → Oct 2014 | — | AnewPharma | Completed | No outcome recorded |
| Phase 1 | NCT01296581 | Feb 2011 → Jan 2014 | cancer | Tyrogenex | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT06577961 | Aug 2024 → Aug 2027 expected | renal cell carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT03583086 | Jul 2018 → Feb 2024 | non-small cell lung carcinoma, small cell lung carcinoma, thymic carcinoma | Vanderbilt-Ingram Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT01784861 | May 2013 → Aug 2020 | adenocarcinoma, pancreatic neuroendocrine neoplasm | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 1/2 | NCT01674569 | Oct 2012 → Feb 2015 | wet macular degeneration | Tyrogenex | Completed | No outcome recorded |
| Phase 214 trials | ||||||
| Phase 2 | NCT07386158 | Jul 2025 → Dec 2026 expected | clear cell renal carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT07047001 | Apr 2025 → Jun 2029 expected | renal cell carcinoma | Dong Wen | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06728852 | Dec 2024 → Dec 2026 expected | non-small cell lung carcinoma | Li-kun Chen | Recruiting | No outcome recorded |
| Phase 2 | NCT06523049 | Aug 2024 → Jul 2026 overdue | renal cell carcinoma | Hao Zeng | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06099184 | Jan → Oct 2024 | diabetic macular edema | EyePoint Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT06406673 | Oct 2023 → Aug 2024 | small cell lung carcinoma | Henan Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05383209 | Sep 2022 → Feb 2024 | diabetic retinopathy | EyePoint Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT05381948 | Jun 2022 → Nov 2023 | wet macular degeneration | EyePoint Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04373369 | Oct 2020 → Aug 2022 | small cell lung carcinoma | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 2 | NCT03904719 | Sep 2019 → Jun 2021 | small cell lung carcinoma | AnewPharma | Unknown | No outcome recorded |
| Phase 2 | NCT03848611 | Apr 2019 → Feb 2021 | non-small cell lung carcinoma | AnewPharma | Unknown | No outcome recorded |
| Phase 2 | NCT03710863 | Nov 2018 → Jan 2022 | age-related macular degeneration | AnewPharma | Unknown | No outcome recorded |
| Phase 2 | NCT03602547 | Jul 2018 → Jul 2019 | mucosal melanoma | AnewPharma | Unknown | No outcome recorded |
| Phase 2 | NCT02348359 | Mar 2015 → Dec 2017 | age related macular degeneration 10, wet macular degeneration | Tyrogenex | Terminated | No outcome recorded |
| Phase 36 trials | ||||||
| Phase 3 | NCT07449936 | Feb 2026 → Oct 2027 expected | diabetic macular edema | EyePoint Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT07449923 | Feb 2026 → Oct 2027 expected | diabetic macular edema | EyePoint Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT07165418 | Sep 2025 → Dec 2028 expected | renal cell carcinoma | Peking University Cancer Hospital & Institute | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06683742 | Nov 2024 → Oct 2026 expected | wet macular degeneration | EyePoint Pharmaceuticals, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06668064 | Oct 2024 → Aug 2026 overdue | wet macular degeneration | EyePoint Pharmaceuticals, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03095040 | Dec 2016 → Feb 2021 | renal cell carcinoma | AnewPharma | Unknown | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 37 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CM082 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01863485 ↗ |
| Known as | EYP-1901 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06099184 ↗ |
| Known as | vorolanib | “EYP-1901, an intravitreal insert containing vorolanib, a pan-VEGF receptor inhibitor packaged in a bioerodible delivery technology (Durasert E™) for sustained delivery” PMID 38881599 ↗ Apr 202413“Vorolanib (X-82) is a novel, oral, multikinase vascular endothelial growth factor (VEGF) receptor/platelet-derived growth factor (PDGF) receptor inhibitor” PMID 30478190 ↗ Nov 2018 “Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study.” PMID 33738668 ↗ Mar 2021 “Vorolanib (X-82, CM082) is a multi-target tyrosine kinase inhibitor.” PMID 32335374 ↗ Apr 2020 |
| Known as | X-82 | “Code Name: CM082 Tablet Other Name: X-82 Dosage and Administration: 25mg BID/50mg QD/50mg BID, P.O., two-week on/two-week off in four-week cycles until disease progression or...” NCT04222842 ↗5“Vorolanib (X-82) is a novel, oral, multikinase vascular endothelial growth factor (VEGF) receptor/platelet-derived growth factor (PDGF) receptor inhibitor” PMID 30478190 ↗ Nov 2018 “Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study.” PMID 33738668 ↗ Mar 2021 |
| Action | Inhibit | “vascular endothelial growth factor (VEGF) receptor/platelet-derived growth factor (PDGF) receptor inhibitor” PMID 30478190 ↗ Nov 2018 |
| Modality | Small molecule | “Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study.” PMID 33738668 ↗ Mar 2021 |
| Route | Oral | “Adult patients with advanced solid tumors received X-82 as tablets or capsules (once daily [q.d.] or b.i.d.)” PMID 30478190 ↗ Nov 2018 |